ECSP045113A - Benzopiranos sustituidos como agonistas selectivos del receptor estrogenico beta - Google Patents

Benzopiranos sustituidos como agonistas selectivos del receptor estrogenico beta

Info

Publication number
ECSP045113A
ECSP045113A EC2004005113A ECSP045113A ECSP045113A EC SP045113 A ECSP045113 A EC SP045113A EC 2004005113 A EC2004005113 A EC 2004005113A EC SP045113 A ECSP045113 A EC SP045113A EC SP045113 A ECSP045113 A EC SP045113A
Authority
EC
Ecuador
Prior art keywords
selective agonists
benzopiranos
strogen
beta
receiver
Prior art date
Application number
EC2004005113A
Other languages
English (en)
Inventor
Jeffrey Alan Dodge
Venkatesh Gary Krishnan
Charles Willis Lugar Iii
Blake Lee Neubauer
Bryan Hurst Norman
Lance Allen Pfeifer
Timothy Ivo Richardson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP045113A publication Critical patent/ECSP045113A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

La presente invención se refiere a nuevos benzopiranos de cicloalquilo y derivados de los mismos, a composiciones que contienen estos compuestos, a su uso como agonistas selectivos del receptor estrogénico beta y a su uso en el tratamiento de enfermedades mediadas por el receptor estrogénico beta tales como cáncer de próstata, hiperplasia prostática benigna, cáncer testicular, cáncer de ovario, cáncer de pulmón, enfermedades cardiovasculares, trastornos neurodegenerativos, incontinencia urinaria, trastornos del sistema nervioso central (SNC), trastornos del tracto gastrointestinal (GI) y osteoporosis
EC2004005113A 2001-11-19 2004-05-19 Benzopiranos sustituidos como agonistas selectivos del receptor estrogenico beta ECSP045113A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33276601P 2001-11-19 2001-11-19
US36362202P 2002-03-11 2002-03-11

Publications (1)

Publication Number Publication Date
ECSP045113A true ECSP045113A (es) 2004-07-23

Family

ID=26988373

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005113A ECSP045113A (es) 2001-11-19 2004-05-19 Benzopiranos sustituidos como agonistas selectivos del receptor estrogenico beta

Country Status (23)

Country Link
US (1) US7217734B2 (es)
EP (1) EP1448544B1 (es)
JP (1) JP4381810B2 (es)
KR (1) KR100950616B1 (es)
CN (1) CN1312147C (es)
AT (1) ATE362471T1 (es)
AU (1) AU2002359283B2 (es)
CA (1) CA2467013C (es)
CY (1) CY1106726T1 (es)
DE (1) DE60220179T2 (es)
DK (1) DK1448544T3 (es)
EA (1) EA007382B1 (es)
EC (1) ECSP045113A (es)
ES (1) ES2286322T3 (es)
HR (1) HRP20040439A2 (es)
HU (1) HU229351B1 (es)
IL (3) IL161325A0 (es)
MX (1) MXPA04004703A (es)
NO (1) NO328563B1 (es)
NZ (1) NZ531850A (es)
PL (1) PL205733B1 (es)
PT (1) PT1448544E (es)
WO (1) WO2003044006A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100374444C (zh) * 2003-04-21 2008-03-12 伊莱利利公司 作为选择性β-雌激素受体激动剂的取代的苯并吡喃化合物
ATE457308T1 (de) 2003-04-21 2010-02-15 Lilly Co Eli Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
BRPI0514974A (pt) 2004-09-07 2008-07-01 Wyeth Corp composto, composição, métodos de tratar ou inibir uma doença ou condição, estados de doença induzidos por radical livre em um mamìfero, dano à junta secundário aos procedimentos artroscópicos ou cirúrgicos em um mamìfero, infertilidade em um mamìfero, de diminuir os nìveis de colesterol, triglicerìdeos, lp(a), ou ldl, de fornecer realce na cognição ou neuroproteção, de contracepção em um mamìfero, e para preparar um composto, e, produto
WO2006044176A1 (en) * 2004-10-18 2006-04-27 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor-beta agonists
CA2587669A1 (en) * 2004-11-18 2006-05-26 Janssen Pharmaceutica N.V. Novel 2h-chromene derivatives as selective estrogen receptor modulators
US8093302B2 (en) 2005-02-15 2012-01-10 Eli Lilly And Company Substituted tetralins as selective estrogen receptor-β agonists
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
TW201043595A (en) 2009-03-13 2010-12-16 Organon Nv Tetrahydronaphthalen-2-ol derivatives
US8063102B2 (en) 2009-03-13 2011-11-22 N.V. Organon Tetrahydronaphthalen-2-ol derivatives
EP3076964A1 (en) 2013-12-05 2016-10-12 Karo Pharma AB Estrogen receptor beta agonists for use in treating mesothelioma
AU2016324495B2 (en) 2015-09-17 2020-12-03 Institute Of Molecular Genetics As Cr, V.V.I. Carborane compounds and methods of use thereof
US20230114408A1 (en) * 2020-03-11 2023-04-13 Ohio State Innovation Foundation Methods of modulating t-cell activation using estrogen receptor beta (erb) agonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3901926A (en) * 1973-04-02 1975-08-26 Abbott Lab Alkylphenyl benzopyrans
DE792292T1 (de) 1995-09-08 1998-09-03 Karo Bio Ab, Huddinge Waisen-rezeptor
WO1999002512A1 (en) * 1997-07-09 1999-01-21 Novo Nordisk A/S Dl-2,3-diaryl-2h-1-benzopyrans
CA2367895A1 (en) 1999-03-17 2000-09-21 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
US6593322B1 (en) 1999-03-17 2003-07-15 Signal Pharmaceuticals, Inc. Compounds and methods for modulation of estrogen receptors
JP2002542187A (ja) 1999-04-16 2002-12-10 アストラゼネカ・アクチエボラーグ エストロゲン−β受容体リガンド
ATE289300T1 (de) 1999-12-30 2005-03-15 Signal Pharm Inc Verbindungen und verfahren zur modulation von estrogen rezeptoren
US7214706B2 (en) 2000-03-01 2007-05-08 Akzo Nobel N.V. Chroman derivatives as estrogenic compounds
DE60130748T2 (de) 2000-03-27 2008-07-17 N.V. Organon Nicht-steroidale tetracyclische verbindungen für östrogen-verwandte behandlungen
GB2361642A (en) 2000-10-24 2001-10-31 Karobio Ab Estrogen receptor beta (ERbeta) agonists for use in cancer treatment
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
TWI306450B (en) 2001-12-13 2009-02-21 Wyeth Corp Substituted phenyl naphthalenes as estrogenic agents
US6630508B1 (en) * 2002-02-11 2003-10-07 Eli Lilly And Company Substituted benzopyrans as selective estrogen receptor β agonists

Also Published As

Publication number Publication date
DE60220179T2 (de) 2008-02-07
IL185867A0 (en) 2008-01-06
HU229351B1 (en) 2013-11-28
DE60220179D1 (de) 2007-06-28
CA2467013C (en) 2010-08-10
HUP0402628A2 (hu) 2005-04-28
NO328563B1 (no) 2010-03-22
US7217734B2 (en) 2007-05-15
PL205733B1 (pl) 2010-05-31
EP1448544A1 (en) 2004-08-25
KR20040063963A (ko) 2004-07-15
EP1448544B1 (en) 2007-05-16
JP4381810B2 (ja) 2009-12-09
MXPA04004703A (es) 2004-08-19
HRP20040439A2 (en) 2005-04-30
EA007382B1 (ru) 2006-10-27
IL185867A (en) 2009-09-22
WO2003044006A1 (en) 2003-05-30
CA2467013A1 (en) 2003-05-30
EA200400695A1 (ru) 2004-12-30
US20040249167A1 (en) 2004-12-09
DK1448544T3 (da) 2007-10-08
AU2002359283B2 (en) 2007-06-21
PL374510A1 (en) 2005-10-31
KR100950616B1 (ko) 2010-04-01
CN1312147C (zh) 2007-04-25
CN1589268A (zh) 2005-03-02
CY1106726T1 (el) 2012-05-23
NZ531850A (en) 2007-01-26
IL161325A0 (en) 2004-09-27
HK1068349A1 (en) 2005-04-29
AU2002359283B8 (en) 2003-06-10
JP2005513027A (ja) 2005-05-12
NO20042583L (no) 2004-06-18
ATE362471T1 (de) 2007-06-15
IL161325A (en) 2008-07-08
AU2002359283A1 (en) 2003-06-10
ES2286322T3 (es) 2007-12-01
PT1448544E (pt) 2007-08-10

Similar Documents

Publication Publication Date Title
PY0119496A (es) Compuestos heterociclicos como ligandos de receptores gabaa
GT200200266A (es) Uso de ureas de benzotiazoles
MXPA03005493A (es) Derivados de bencimidazol y piridilmidazol como ligandos para receptores gaba.
UY29317A1 (es) Derivados novedosos pirrolidilo de compuestos heteroaromáticos
ECSP034428A (es) Ciclopentanoindoles, composiciones conteniendo tales compuestos y su uso
GT200200148A (es) Compuestos de heteroarilo biciclicos fusionados substituidos con heteroarilo como ligandos del receptor gaba a
DE602004025460D1 (de) Substituierte benzopyrane als selektive antagonisten am östrogenrezeptor-beta
IL185867A0 (en) Substituted benzopyrans as selective estrogen receptor-beta agonists
MXPA04002070A (es) Compuestos de indazol sustituidos para el tratamiento de la inflamacion.
MXPA04002682A (es) Compuestos pirazolilo sustituidos para el tratamiento de la inflamacion.
PL2444085T3 (pl) Związki diarylohydantoinowe jako antagoniści receptora androgenów do leczenia raka
PA8583201A1 (es) Nuevos compuestos de pirazol como inhibidores del factor de crecimiento transformante (tgf)
CR20120119A (es) Moduladores del receptor glucocorticoide
CU23464B7 (es) (1,8)naftidirin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
CR9442A (es) Nuevos compuestos farmaceuticos
MXPA04002042A (es) Compuestos de bencimidazol sustituidos y su uso para el tratamiento del cancer.
SI1626974T1 (sl) Substituirani benzopirani kot selektivni agonistiestrogenskega receptorja beta
GT200500332A (es) Azabenzoxazoles para el tratamiento de trastornos del snc
PA8567701A1 (es) Agonistas del receptor b3-adrenergico
MX2008002366A (es) Antagonistas triciclicos fusionados de mglur1 como agentes terapeuticos.
BRPI0519201A2 (pt) moduladores de delta-opiàide tricÍclico
Li et al. 7-Cycloalkylcamptothecin derivatives: Preparation and biological evaluation
PA8633601A1 (es) Profarmacos de esteroides con accion androgenica
DE60140700D1 (de) Thienoi2,3-B pyridin-derivate als Antagonisten des Gonadotropin-freisetzenden Hormons
BR0112147A (pt) Tienopirrolidinonas